Street View: Johnson & Johnson's strength in product pipeline to drive growth

** Johnson & Johnson JNJ halved its expectations for costs this year related to new tariffs and raised full-year sales and profit forecast on Wednesday after a strong quarter for its flagship cancer drug Darzalex and cardiovascular devices

INNOVATIVE MEDICINES SEGMENT TO LEAD GAINS

** J.P.Morgan ("neutral," PT: $185) says JNJ's underlying business is well positioned and capable of generating over 5% revenue growth with the innovative medicines segment and medtech portfolio supporting growth

** Morningstar (fair value: $172) says on potential pharmaceutical tariffs, JNJ is in a good position with most US-bound products already made in the U.S.

** TD Cowen ("buy," PT: $185) notes JNJ has numerous milestones ahead in the innovation medicine pipeline including TAR-200 for bladder cancer that is set to be commercialized later this year

** Leerink Partners ("market perform," PT: $171) says TAR-200 is well positioned to gain significant market share, aiding co's growth prospects